Latent Tuberculosis Infection in Cancer Patients
1. To evaluate the performance of the new T-SPOT.TB test and the conventional TST for screening of Latent Tuberculosis infections in patients with cancer and those undergoing Hematopoietic Stem Cell Transplant.
- To examine the factors associated with positive response to T-SPOT.TB and the TST (tuberculin skin test) in patients with anergy.
- To determine the impact of immunosuppressive and antineoplastic therapy on the screening performance of T-SPOT.TB and the TST in cancer patients.
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Latent Mycobacterium Tuberculosis Infection Among Cancer Patients|
- Rate of Positive Results of T-SPOT.TB (%) [ Time Frame: Study period 2 Years ] [ Designated as safety issue: No ]Number participants with postitive T-SPOT.TB test results compared to total positive results, derived from Center for Disease Control (CDC) Criteria used for LTBI positive skin test (i.e. a tuberculin skin test (TST) with 5 mm or more of induration). For those individuals with >5 mm induration on TST, chest radiograph performed. Fisher's exact test used to assess the association between categorical variables and the testing results of T-SPOT.TB or TST.
Biospecimen Retention: Samples With DNA
|Study Start Date:||June 2007|
|Study Completion Date:||May 2011|
|Primary Completion Date:||May 2011 (Final data collection date for primary outcome measure)|
Latent Tuberculosis Infection
Patients with cancer at risk for developing active tuberculosis (TB).
Other: T-SPOT TB test
Extra blood draw, followed by ten minutes rest and the injection of Tuberculin subcutaneously on forearm.
Show Detailed Description
Please refer to this study by its ClinicalTrials.gov identifier: NCT00507754
|United States, Texas|
|UT MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Amar Safdar, MD||M.D. Anderson Cancer Center|